Tied to improvements in pain, anxiety, depression among breast cancer survivors with fatigue
Researchers examined recall and cancer detection rates for digital breast tomosynthesis (DBT) versus digital mammography (DM).
The Food and Drug Administration (FDA) has approved Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) for the treatment of HER2-overexpressing breast cancer. Herceptin Hylecta is a combination of trastuzumab, an HER2/neu receptor antagonist, and hyaluronidase, an endoglycosidase used to increase the dispersion and absorption of coadministered drugs when administered subcutaneously. The product contains the same active ingredient…
Using a cohort of women from the POSH Study, researchers sought to determine risk factors for changes in weight among younger, premenopausal women receiving adjuvant chemotherapy for early-stage breast cancer.
A randomized study sought to determine if an Internet-based cognitive behavioral therapy program focused on managing treatment-induced menopausal symptoms has the potential to help breast cancer survivors adhere to long-term endocrine therapy.